AlphAIAlphAI — Financial news for AI agents
stocktwits.comSEP 182 min read$HELP

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Helus Pharma (HELP) shares rose to a 52-week high of $15.15 before falling 11% after Barclays initiated coverage with an Overweight rating and $35 price target. The company awaits Q4 trial results for its psychedelic drug HLP003, with FDA Breakthrough Therapy status. Analysts' average price target is $41.40, implying 195% upside. HELP has gained 53% year-to-date.

Original reporting
stocktwits.com
Published Sep 18, 2026, 7:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 7:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$HELP
Bullish
medium confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$HELPBullishMed
01

Why it matters

Barclays' upgrade adds fresh upside expectations, potentially driving short‑term buying pressure ahead of trial data.

02

Market read

Analyst upgrade with a high target may spark a price rally, especially as investors anticipate trial results.

03

What to watch

Execution risk of the trial and the company's limited cash runway beyond the $50 M raise.

Relevance 7/10Novelty 7/10Timing: pre‑market Friday

Background

Helus Pharma is developing serotonergic agonist psychedelics for depression and anxiety, with a late‑stage trial readout expected in Q4.

Company-level read

Ticker impact

$HELPBullishMedium confidence
Context

Barclays initiated coverage on Helus Pharma with an Overweight rating and a $35 price target, a fresh analyst upgrade that moved the stock.

Expected impact

Potential rally toward the $35 target over the next weeks if trial results are positive.

Evidence & confidence

Analyst upgrades with strong targets often trigger buying pressure, especially ahead of a pivotal trial readout.

Market effects

Sector

Positive coverage may lift other psychedelic‑therapy biotech stocks.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad macro effect.

Counterpoint

What could challenge this read

If the upcoming trial fails, the high target could lead to a sharp correction.

Key entities

  • company
    Helus Pharma

    Biotech firm developing psychedelic therapies.

  • analyst_firm
    Barclays

    Investment bank that initiated coverage with a $35 price target.

Read at source← All news

Related articles

AUG 14
$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

finanznachrichten.de6 min
JUL 21
$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

prnewswire.com2 min
JUL 17
$LLYMedAI 8/10

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

prnewswire.com7 min
JUN 25
$HELPMedAI 8/10

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.

montrealgazette.com2 min
SEP 21
$TPBHigh

Why Turning Point Brands Stock Dived by 10% Today

Turning Point Brands (TPB) stock fell 10% on Monday due to unexpected CEO departure and a cut in EBITDA guidance. CEO Graham Purdy is leaving for personal reasons, and David Glazek will take over. The company reduced its full-year EBITDA forecast to $70M from $80M but maintained sales estimates for its oral tobacco products.

fool.com2 min